Biovica International AB (publ) (BIOVIC-B) - Total Liabilities
Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has total liabilities worth Skr31.14 Million SEK (≈ $3.35 Million USD) as of July 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOVIC-B operating cash flow to assess how effectively this company generates cash.
Biovica International AB (publ) - Total Liabilities Trend (2014–2025)
This chart illustrates how Biovica International AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check Biovica International AB (publ) asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Biovica International AB (publ) Competitors by Total Liabilities
The table below lists competitors of Biovica International AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
India | Rs648.59 Million |
|
Phoenix New Media Limited
NYSE:FENG
|
USA | $541.82 Million |
|
Neola Medical AB
ST:NEOLA
|
Sweden | Skr4.15 Million |
|
STO Co. Ltd
KQ:098660
|
Korea | ₩54.54 Billion |
|
GEN Restaurant Group, Inc. Class A Common Stock
NASDAQ:GENK
|
USA | $231.85 Million |
|
Huachen AI Parking Management Technology Holding Co Ltd
NASDAQ:HCAI
|
USA | $21.65 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Biovica International AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOVIC-B market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.56 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biovica International AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biovica International AB (publ) (2014–2025)
The table below shows the annual total liabilities of Biovica International AB (publ) from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | Skr21.74 Million ≈ $2.34 Million |
-37.46% |
| 2024-04-30 | Skr34.77 Million ≈ $3.74 Million |
+3.32% |
| 2023-04-30 | Skr33.65 Million ≈ $3.62 Million |
+22.18% |
| 2022-04-30 | Skr27.54 Million ≈ $2.96 Million |
+175.73% |
| 2021-04-30 | Skr9.99 Million ≈ $1.07 Million |
-17.05% |
| 2020-04-30 | Skr12.04 Million ≈ $1.30 Million |
+37.43% |
| 2019-04-30 | Skr8.76 Million ≈ $942.93K |
+24.14% |
| 2018-04-30 | Skr7.06 Million ≈ $759.55K |
+25.19% |
| 2017-04-30 | Skr5.64 Million ≈ $606.74K |
+73.26% |
| 2016-04-30 | Skr3.25 Million ≈ $350.18K |
-65.54% |
| 2015-04-30 | Skr9.44 Million ≈ $1.02 Million |
+134.67% |
| 2014-04-30 | Skr4.02 Million ≈ $433.09K |
-- |
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more